Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Akebia Therapeutics Inc (NASDAQ: AKBA) closed at $2.78 in the last session, up 1.09% from day before closing price of $2.75. In other words, the price has increased by $1.09 from its previous closing price. On the day, 2.4 million shares were traded. AKBA stock price reached its highest trading level at $2.81 during the session, while it also had its lowest trading level at $2.69.
Ratios:
We take a closer look at AKBA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 7.21 whereas as Long-Term Debt/Eq ratio is at 6.10.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik sold 41,314 shares for $3.67 per share. The transaction valued at 151,622 led to the insider holds 503,586 shares of the business.
Ostrowski Erik bought 41,314 shares of AKBA for $151,622 on Jun 30 ’25. On Jun 09 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 15,000 shares for $4.01 each. As a result, the insider received 60,150 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 737103232 and an Enterprise Value of 795692224. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.62 while its Price-to-Book (P/B) ratio in mrq is 25.02. Its current Enterprise Value per Revenue stands at 3.906 whereas that against EBITDA is 34.08.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.64, which has changed by 1.1221373 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $1.27. The 50-Day Moving Average of the stock is -8.24%, while the 200-Day Moving Average is calculated to be 2.85%.
Shares Statistics:
According to the various share statistics, AKBA traded on average about 3.54M shares per day over the past 3-months and 2765030 shares per day over the past 10 days. A total of 263.04M shares are outstanding, with a floating share count of 254.74M. Insiders hold about 3.92% of the company’s shares, while institutions hold 41.61% stake in the company. Shares short for AKBA as of 1759190400 were 29401452 with a Short Ratio of 8.30, compared to 1756425600 on 27090731. Therefore, it implies a Short% of Shares Outstanding of 29401452 and a Short% of Float of 11.1999996.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.02 and -$0.04 for the fiscal current year, implying an average EPS of -$0.03. EPS for the following year is $0.26, with 2.0 analysts recommending between $0.41 and $0.11.
Revenue Estimates
According to 5 analysts,. The current quarter’s revenue is expected to be $52.06M. It ranges from a high estimate of $65.5M to a low estimate of $45.54M. As of. The current estimate, Akebia Therapeutics Inc’s year-ago sales were $37.43MFor the next quarter, 5 analysts are estimating revenue of $54.1M. There is a high estimate of $76.4M for the next quarter, whereas the lowest estimate is $38.85M.
A total of 5 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $261.7M, while the lowest revenue estimate was $204.2M, resulting in an average revenue estimate of $226M. In the same quarter a year ago, actual revenue was $160.18MBased on 5 analysts’ estimates, the company’s revenue will be $298.52M in the next fiscal year. The high estimate is $396.3M and the low estimate is $227.9M.
